Mechanisms of responsiveness to and resistance against trabectedin in murine models of human myxoid liposarcoma

Autor: Paolo G. Casali, Roberta Sanfilippo, M. D'Incalci, Maurizio Callari, Marta Barisella, Marina Meroni, Roberta Frapolli, Chiara Fabbroni, Ilaria Craparotta, Nicolò Panini, Laura Mannarino, Sergio Marchini, Sara Ballabio, Ezia Bello

Publikováno v: Genomics. 113:3439-3448

Myxoid liposarcoma (MLPS) is a rare soft-tissue sarcoma characterised by the expression of FUS-DDIT3 chimera. Trabectedin has shown significant clinical anti-tumour activity against MLPS. To characterise the molecular mechanism of trabectedin sensiti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fb4c14c1bad8060caed63aab31d4b18d
https://doi.org/10.1016/j.ygeno.2021.07.028

Trabectedin Followed by Irinotecan Can Stabilize Disease in Advanced Translocation-Positive Sarcomas with Acceptable Toxicity

Autor: J. Herzog, F. von Klot-Heydenfeldt, S. Jabar, A. Ranft, C. Rossig, U. Dirksen, J. Van den Brande, M. D’Incalci, I. von Luettichau, P. J. Grohar, W. E. Berdel, St. Burdach

Publikováno v: Sarcoma, Vol 2016 (2016)

Background. Preclinical data indicate that trabectedin followed by irinotecan has strong synergistic effects on Ewing sarcoma. This is presumably due to hypersensitization of the tumor cells to the camptothecin as an effect of trabectedin in addition

Externí odkaz: https://doaj.org/article/42a82ead95244ea38f1c18b197b6a1fe

European experts consensus: BRCA/homologous recombination deficiency testing in first-line ovarian cancer

Autor: I. Vergote, A. González-Martín, I. Ray-Coquard, P. Harter, N. Colombo, P. Pujol, D. Lorusso, M.R. Mirza, B. Brasiuniene, R. Madry, J.D. Brenton, M.G.E.M. Ausems, R. Büttner, D. Lambrechts, M. Ausems, J. Brenton, M. Abreu, S. Balboni, S. Banerjee, M. Barberis, M.P. Barretina Ginesta, J.-F. Baurain, M. Bignami, L. Bjorge, P. Blecharz, I. Bruchim, M. Capilna, N. Cerana, A. Cicchetti, D. Collins, N. Concin, M. D’Incalci, B. Davidson, T. de la Motte Rouge, P. De Iaco, F. Demirkiran, H. Denys, T. Doerk, A. Dorum, A. Ferrero, A.P. Fidalgo, M. Genuardi, L. Gladieff, R. Glasspool, C. Grimm, M. Gultekin, E. Hahnen, A. Hasenburg, A. Hegmane, V. Heinzelmann, E. Hogdall, R. Janavicius, S. Jarmalaite, R. Kalachand, R. Kaneva, S. Kilickap, R. Kocian, D. Kolencik, R. Kristeleit, A. Kryzhanivska, A. Leary, B. Lemley, M. Ligtenberg, J.A. López-Guerrero, C.J. Lord, E. Avall-Lundqvist, J. Maenpaa, S. Mahner, F. Marmé, C. Marth, I. McNeish, S. Merkelbach-Bruse, M. Mourits, N. Normanno, A. Oaknin, K. Ojamaa, C. Papdimitriou, F. Penault-Llorca, A.M. Perrone, S. Pignata, E. Pikarsky, E. Rouleau, M. Rubio, A. Sapino, B. Schmalfeldt, J. Sehouli, R. Shapira, K.D. Steffensen, V. Sukhin, J. Syrios, Z. Szallasi, C. Taskiran, M. Terzic, M. Tischkowitz, I. Toth, K. Van de Vijver, M.A. Vardar, B. Wasag, P. Wimberger, E. Witteveen

Publikováno v: Annals of Oncology, 33, 3, pp. 276-87
Vergote, I, González-Martín, A, Ray-Coquard, I, Harter, P, Colombo, N, Pujol, P, Lorusso, D, Mirza, M R, Brasiuniene, B, Madry, R, Brenton, J D, Ausems, M G E M, Büttner, R, Lambrechts, D, European experts’ consensus group & Dahl Steffensen, K 2022, ' European experts consensus : BRCA/homologous recombination deficiency testing in first-line ovarian cancer ', Annals of Oncology, vol. 33, no. 3, pp. 276-287 . https://doi.org/10.1016/j.annonc.2021.11.013
ANNALS OF ONCOLOGY
Annals of Oncology, 33, 276-87

BACKGROUND: Homologous recombination repair (HRR) enables fault-free repair of double-stranded DNA breaks. HRR deficiency is predicted to occur in around half of high-grade serous ovarian carcinomas. Ovarian cancers harbouring HRR deficiency typicall

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::048b3ea84583ffb10df0f113446b4777

PEGylated recombinant human hyaluronidase (PEGPH20) pre-treatment improves intra-tumour distribution and efficacy of paclitaxel in preclinical models

Autor: Marina Meroni, Lavinia Morosi, Ilaria Fuso Nerini, Roberta Frapolli, Barbara Blouw, Lucia Minoli, Enrico Davoli, Paolo Ubezio, Luca Porcu, M. D'Incalci, Massimo Zucchetti, Nicolò Panini, Marika Colombo, David W. Kang

Publikováno v: Journal of Experimental & Clinical Cancer Research : CR
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-13 (2021)

Background Scarce drug penetration in solid tumours is one of the possible causes of the limited efficacy of chemotherapy and is related to the altered tumour microenvironment. The abnormal tumour extracellular matrix (ECM) together with abnormal blo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c192e2b977107ce328cd64d0d5191a5
http://europepmc.org/articles/PMC8434701

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.